To the Editor In the recent case report by Poondru et al, a patient with lepromatous leprosy was treated with monthly multidrug antibiotic therapy (rifampin, moxifloxacin, and minocycline) following consultation with the US National Hansen’s Disease Program (NHDP). The patient also initiated treatment with methotrexate and prednisone “to reduce the risk of erythema nodosum leprosum.”1 On behalf of several US leprosy experts, we are concerned about the lack of evidence supporting these treatment recommendations, which diverge from published NHDP guidelines recommending daily antibiotic therapy with the possible exception of monthly rifampin.
BT - JAMA dermatology C1 -https://www.ncbi.nlm.nih.gov/pubmed/38809538
DA - 05/2024 DO - 10.1001/jamadermatol.2024.1353 J2 - JAMA Dermatol LA - eng M3 - Letter to the Editor N2 -To the Editor In the recent case report by Poondru et al, a patient with lepromatous leprosy was treated with monthly multidrug antibiotic therapy (rifampin, moxifloxacin, and minocycline) following consultation with the US National Hansen’s Disease Program (NHDP). The patient also initiated treatment with methotrexate and prednisone “to reduce the risk of erythema nodosum leprosum.”1 On behalf of several US leprosy experts, we are concerned about the lack of evidence supporting these treatment recommendations, which diverge from published NHDP guidelines recommending daily antibiotic therapy with the possible exception of monthly rifampin.
PY - 2024 T2 - JAMA dermatology TI - Leprosy-Insufficient Evidence for Monthly Multidrug Therapy. SN - 2168-6084 ER -